Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib

The Phase II  COVALENT-111 study results highlighted that icovamenib maintained a favorable safety profile throughout the 52-week observation period, with no serious treatment-related adverse events. Additionally, the study showed statistically significant reductions in HbA1c levels among certain patient subgroups, suggesting icovamenib’s potential to transform diabetes treatment.“We are encouraged by the durability of icovamenib’s effect observed nine months post-dosing at Week 52,” said Mick Hitchcock, Ph ...